Ahmedabad, Oct 25, Torrent Pharma announced Q2 FY25 results today.
According to a statement issued by the company here today Revenue & profitability: Revenue at Rs. 2,889 crores grew by 9%. Gross Margin: 76.5%, Op. EBITDA margin at 32.5%. Op. EBITDA at Rs.939 crores, up by 14%.
Net Profit after tax at Rs. 453 crores, up by 17%.
Insulin revenues were impacted this quarter due to scheduled shutdown taken in the month of August for maintenance activities. The facility will be released for manufacturing in December. Shortfall is significantly planned to be recovered in Quarter 4 of this year and consequently there will not be any impact on a full year basis.
Adjusted for the above, the underlying revenue growth for the quarter is 10% with Operating EBITDA growth at 16%.